Answers are grounded in this paper and cite their sources.
All four patients described in this case series successfully transitioned from lanadelumab to berotralstat monotherapy for long-term prophylaxis without significant complications and without the use of a complex transition protocol. The decision to transition to berotralstat monotherapy and how the transition should be achieved was discussed between patient and physician, ensuring that the comfort and perspectives of the patients were considered during the treatment transition. This report highlights the importance of individualization of HAE management plans to address both the disease and treatment burdens of HAE, and thus to provide the best possible quality of life for each patient.
No takes yet. Share an insight, caveat, or question.
Gower et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: